Blueprint Medicines (BPMC) IPO Opens Up 30%

Blueprint Medicines' (Nasdaq: BPMC) IPO opened for trading at $23.40 after pricing 8,145,834 shares of its common stock at $18.

Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for the offering. Wedbush PacGrow is also acting as a co-manager for the offering.

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

You May Also Be Interested In

• BOA Acquisition Corp. II raises $143.75M in Nasdaq IPO
• Braveheart Bio raises $439.9M in upsized Nasdaq IPO
• CEVA Inc. (CEVA) PT Lowered to $45 at TD Cowen